1. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases;Ishikawa;Respir Investig,2012
2. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–173.
3. Statement on Sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and other Granulomatous Disorders (WASOG), adapted by the ATS Board of Directors and by the ERS Executive Committee February 1999. Am J Respir Crit Care Med. 1999;160(2):736-55.
4. Biomarkers in sarcoidosis: a review;Ahmadzai H Sheng;Current Biomarker Findings,2014
5. Proteomic approaches for studying human parenchymal lung diseases;Kinnula;Expert Rev Proteomics,2009